@conference {941, title = {Clinical course of migraine during the COVID-19 Lockdown}, booktitle = {International Headache Congress 2021}, year = {2021}, month = {2021}, publisher = {International Headache Society \& European Headache Federation}, organization = {International Headache Society \& European Headache Federation}, address = {Virtual Congress}, abstract = {
Objective: Previous studies have demonstrated that migraine can worsen due to stress, changes in lifestyle habits or infections. We hypothesize that changes during coronavirus disease 2019 (COVID-19) lockdown might have worsened the clinical course of migraine.
Methods: Retrospective survey study collecting demographic data, clinical variables related to headache (frequency), migraine (subjective worsening, frequency, and intensity), lockdown, and symptoms of post-traumatic stress from migraine patients followed-up at three Headache Units between June-July 2020.
Results: 222 subjects were included. Among them, 201/222 (90.5\%) were women, aged 42.5 +- 12.0 (mean +- SD). Subjective improvement of migraine was reported in 31/222 participants (14.0\%), while worsening in 105/222 (47.3\%) and was associated with changes in migraine triggers such as stress related to going outdoors and intake of specific foods/drinks. Intensity of attacks increased in 67/222 patients (30.2\%), and it was associated with the subjective worsening, female sex, recent insomnia, and use of acute medication during a headache. An increase in monthly days with any headache was observed in 105/222 patients (47.3\%) and was related to symptoms of post-traumatic stress, older age and living with five or more people.
Conclusion: Approximately half the migraine patients reported worsening of their usual pain during the lockdown; worsening was related to changes in triggers and the emotional impact of the lockdown.
}, url = {https://journals.sagepub.com/doi/pdf/10.1177/03331024211034005}, author = {Gonzalez-Martinez, Alicia and {\'A}lvaro Planchuelo-G{\'o}mez and {\'A}ngel L. Guerrero and Garc{\'\i}a-Azor{\'\i}n, David and Santos-Lasaosa, Sonia and P{\'e}rez-Navarro, Mar{\'\i}a P and Odriozola-Gonz{\'a}lez, Paula and Irurtia, Mar{\'\i}a Jes{\'u}s and Quintas, Sonia and Rodrigo de Luis-Garc{\'\i}a and Ana B Gago-Veiga} } @article {952, title = {Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown}, journal = {Neurological Sciences}, volume = {42}, year = {2021}, pages = {5087-5092}, issn = {1590-3478}, doi = {10.1007/s10072-021-05180-8}, url = {https://doi.org/10.1007/s10072-021-05180-8}, author = {Gonzalez-Martinez, Alicia and {\'A}lvaro Planchuelo-G{\'o}mez and {\'A}ngel L. Guerrero and Garc{\'\i}a-Azor{\'\i}n, David and Santos-Lasaosa, Sonia and Navarro-P{\'e}rez, Mar{\'\i}a Pilar and Odriozola-Gonz{\'a}lez, Paula and Irurtia, Mar{\'\i}a Jes{\'u}s and Quintas, Sonia and de Luis-Garc{\'\i}a, Rodrigo and Ana B Gago-Veiga} } @article {944, title = {Evaluation of the Impact of the COVID-19 Lockdown in the Clinical Course of Migraine}, journal = {Pain Medicine}, volume = {22}, year = {2021}, month = {2021}, pages = {2079-2091}, abstract = {Objective: Previous studies have demonstrated that emotional stress, changes in lifestyle habits and infections can worsen the clinical course of migraine. We hypothesize that changes in habits and medical care during coronavirus disease 2019 (COVID-19) lockdown might have worsened the clinical course of migraine.
Design: Retrospective survey study collecting online responses from migraine patients followed-up by neurologists at three tertiary hospitals between June and July 2020.
Methods: We used a web-based survey that included demographic data, clinical variables related with any headache (frequency) and migraine (subjective worsening, frequency, and intensity), lockdown, and symptoms of post-traumatic stress.
Results: The response rate of the survey was 239/324 (73.8\%). The final analysis included 222 subjects. Among them, 201/222 (90.5\%) were women, aged 42.5 +- 12.0 (mean+-SD). Subjective improvement of migraine during lockdown was reported in 31/222 participants (14.0\%), while worsening in 105/222 (47.3\%) and was associated with changes in migraine triggers such as stress related to going outdoors and intake of specific foods or drinks. Intensity of attacks increased in 67/222 patients (30.2\%), and it was associated with the subjective worsening, female sex, recent insomnia, and use of acute medication during a headache. An increase in monthly days with any headache was observed in 105/222 patients (47.3\%) and was related to symptoms of post-traumatic stress, older age and living with five or more people.
Conclusions: Approximately half the migraine patients reported worsening of their usual pain during the lockdown. Worse clinical course in migraine patients was related to changes in triggers and the emotional impact of the lockdown.
}, keywords = {COVID-19, Headache, Lockdown, Migraine, SARS-CoV-2}, issn = {1526-4637}, doi = {10.1093/pm/pnaa449}, url = {https://doi.org/10.1093/pm/pnaa449}, author = {Gonzalez-Martinez, Alicia and {\'A}lvaro Planchuelo-G{\'o}mez and {\'A}ngel L. Guerrero and Garc{\'\i}a-Azor{\'\i}n, David and Santos-Lasaosa, Sonia and Navarro-P{\'e}rez, Mar{\'\i}a Pilar and Odriozola-Gonz{\'a}lez, Paula and Irurtia, Mar{\'\i}a Jes{\'u}s and Quintas, Sonia and Rodrigo de Luis-Garc{\'\i}a and Ana B Gago-Veiga} } @conference {942, title = {Has onabotulinumtoxinA follow-up delay during COVID-19 lockdown affected the migraine course?}, booktitle = {International Headache Congress 2021}, year = {2021}, month = {2021}, publisher = {International Headache Society \& European Headache Federation}, organization = {International Headache Society \& European Headache Federation}, address = {Virtual Congress}, abstract = {Objective: During the COVID-19 pandemic face-to-face procedures have been postponed. We aim to evaluate the impact of onabotulinumtoxinA follow-up delay in migraine during COVID-19 pandemic.
Methods: Subjective worsening, intensity of migraine attacks and frequency of headache and migraine were retrospectively compared between patients with unmodified and interrupted onabotulinumtoxinA follow-up in Headache Units.
Results: We included 67 patients with chronic migraine or high-frequency episodic migraine under onabotulinumtoxinA treatment, 65 (97.0\%) female,
44.5 +- 12.1 years old. Treatment administration was voluntarily delayed in 14 (20.9\%) patients and nine (13.4\%) were unable to continue follow-up. Patients with uninterrupted follow-up during lockdown presented 8.4 and 8.1 less monthly days with headache (adjusted p = 0.011) and migraine attacks (adjusted p = 0.009) compared to patients whose follow-up was interrupted, respectively.
Conclusion: Involuntary delay of onabotulinumtoxinA follow-up in patients with migraine due to COVID-19 pandemic was associated with a higher frequency of headache and migraine attacks. Safe administration of onabotulinumtoxinA during lockdown should be promoted.